Medicare Price Negotiation Savings Would Rise To $101Bn With Revisions To Legislation – CBO
Executive Summary
Latest version of Medicare price negotiation and price inflation rebate provisions are expected to lower federal government costs by about $200bn over 10 years.
You may also be interested in...
‘A Forever Battle:’ Patent Reform, Launch Prices, And Where Lower Rx Price Advocates Will Go Next
Pharma’s opponents believe passage of the Inflation Reduction Act represents a momentum shift that will make it easier for politicians (even some Republicans) to take on the industry. They’ll need to count on that as they still have a long list of targets ahead on their lower-drug pricing agenda.
Don’t Believe The Lack Of Hype: US Drug Price Reform Is Biggest Ever
The narrative about the Democrats’ march toward comprehensive drug pricing legislation in the US has emphasized what has dropped out of the original proposal. That obscures the bigger picture: it will be by far the most impactful drug pricing legislation ever enacted in the US.
Part D Price Negotiation Round One: Several Likely Candidates May Not Feel The Cut
Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.